Jonzobot,

The post AHA corporate presentation slide 19 showed no difference between the atorvastatin and rosuvastatin groups for the primary 3-point MACE endpoint. Recall the synergy was for plaque reduction in ASSURE; plaque volume was not measured in BETonMACE. Also recall that most MACE events in the Phase 2s were not the strict 3-point variety, and for these Phase 2 5-point MACE events, apabetalone seemed to lower MACE incidence with both statin types. See this post.

BearDownAZ